For example, inhibiting USP2a (ubiquitin-specific protease 2a)-mediated MDMX deubiquitination and stabilization and developing MDMX PROTACs (proteolysis targeting chimeras) should be considered for developing selective MDMX inhibitors for cancer therapy (125, 126). Here, MDM4 is linked to cancer.